TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22645292

Group type: EXPERIMENTAL
Intervention: Sustained ventricular tachycardia/ventricular fibrillation (VT/VF) ≤48 hours after enrollment
Number of subjects: 9211

Group type: EXPERIMENTAL
Intervention: Sustained ventricular tachycardia/ventricular fibrillation (VT/VF) >48 hours after enrollment
Number of subjects: 9211

Group type: EXPERIMENTAL
Intervention: Sustained ventricular tachycardia/ventricular fibrillation (VT/VF)
Number of subjects: 9211
Study: 20644185

Group type: EXPERIMENTAL
Intervention: Guided Care
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 49
Study: 17227743

Group type: EXPERIMENTAL
Intervention: Homeopathic Arnica 30c, 2 tablets 6 times on the first post-operative day and then 2 tablets twice a day for the next 7 days
Number of subjects: 190

Group type: COMPARATOR
Intervention: Identical placebo, 2 tablets 6 times on the first post-operative day and then 2 tablets twice a day for the next 7 days
Number of subjects: 190
Study: 15155712

Group type: EXPERIMENTAL
Intervention: VIP at doses ranging from 25 to 800 pmol
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Inhibition of H1 receptors
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combined H1‐receptor inhibition and NO synthase inhibition
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: H2‐receptor inhibition
Number of subjects: 43
Study: 11268267

Group type: EXPERIMENTAL
Intervention: Leukoreduced transfusion
Number of subjects: 531

Group type: COMPARATOR
Intervention: Unmodified transfusion
Number of subjects: 531
Study: 9530594

Group type: EXPERIMENTAL
Intervention: Videokeratography indices
Number of subjects: 241

Group type: COMPARATOR
Intervention: Ultrasonic pachymetry measurements
Number of subjects: 241
Study: 7985670

Group type: EXPERIMENTAL
Intervention: Dialyzer with high reuse (mean, 13.8 uses)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Dialyzer with low reuse (mean, 3.8 uses)
Number of subjects: 436
Study: 2609672

Group type: EXPERIMENTAL
Intervention: Intravenous Doxepin treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oral Doxepin treatment
Number of subjects: 45
Study: 48000

Group type: EXPERIMENTAL
Intervention: Elective induction of labour
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control (managed expectantly until 41 weeks)
Number of subjects: 111
Study: 31634766

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28562839

Group type: EXPERIMENTAL
Intervention: Pedometer with step-count goal setting
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pedometer only
Number of subjects: 32
Study: 26483357

Group type: EXPERIMENTAL
Intervention: Dronabinol 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dronabinol 30 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dronabinol 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dronabinol 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dronabinol 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxycodone 30 mg
Number of subjects: 12
Study: 23684127

Group type: EXPERIMENTAL
Intervention: Machine learning methodology using pre-treatment EEG data for predicting response to SSRI treatment
Number of subjects: 0
Study: 21275593

Group type: EXPERIMENTAL
Intervention: Standard treatment coverage (80%-90%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High treatment coverage (over 90%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual treatment for 3 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graduation rule (halt treatment based on absence of follicular trachoma or infection)
Number of subjects: 0
Study: 19783552

Group type: EXPERIMENTAL
Intervention: Weekly gemcitabine (1000 mg/m²) and split-dose cisplatin (40 mg/m²) administered on days 1 and 8 at 3-week intervals for four cycles.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Weekly gemcitabine and split-dose cisplatin
Number of subjects: 45
Study: 16423116

Group type: EXPERIMENTAL
Intervention: Collaborative Discovery (CD) teaching method
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Demonstration and Practice (DP) teaching method
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (usual ward teaching sessions)
Number of subjects: 80
Study: 12608026

Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 12658

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12658
Study: 16571153

Group type: EXPERIMENTAL
Intervention: Tomatoes, tomato juice, tomato purée (12.5 mg lycopene/d for 4 weeks)
Number of subjects: 0
Study: 10676542

Group type: EXPERIMENTAL
Intervention: Classroom-centered (CC) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family-school partnership (FSP) intervention
Number of subjects: 0
Study: 8739513

Group type: EXPERIMENTAL
Intervention: GnRH agonist (300 micrograms and 600 micrograms per day by nasal spray for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IUD users (control group)
Number of subjects: 0
Study: 2017313

Group type: EXPERIMENTAL
Intervention: defibrotide 400 mg b.i.d. IM (starting the day before surgery and continuing for the following 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: calcium heparin 5,000 IU t.i.d. SC (since the day of surgery and for the following 7 days)
Number of subjects: 20
Study: 7149870

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control
Number of subjects: 223
Study: 31888883

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol/kg/min) infusion for 150 min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol/kg/min) + insulin (1 mU/kg/min) infusion for 120 min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 15
Study: 30566166

Group type: EXPERIMENTAL
Intervention: Solid food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liquid food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semi-solid food
Number of subjects: 0
Study: 29077924

Group type: EXPERIMENTAL
Intervention: Perioperative Behavioral Therapy (BPMT)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 374
Study: 26585724

Group type: EXPERIMENTAL
Intervention: Pretreatment of anxiety before surgery
Number of subjects: 27
Study: 25349296

Group type: EXPERIMENTAL
Intervention: Reirradiation of painful osseous metastases
Number of subjects: 850
Study: 21790779

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 200 μg b.i.d. via AeroChamber Plus
Number of subjects: 26

Group type: COMPARATOR
Intervention: Inhaled beclomethasone dipropionate (BDP) 200 μg b.i.d. via Volumatic spacer
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: UFC/creatinine data
Number of subjects: 26
Study: 19778452

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 117
Study: 17437654

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dexamethasone 0.5 mg kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Midazolam 50 microg kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Midazolam 50 microg kg‐1 and Dexamethasone 0.5 mg kg‐1
Number of subjects: 100
Study: 15333081

Group type: EXPERIMENTAL
Intervention: Biphasic cardioversion (Bi)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Monophasic cardioversion (Mo)
Number of subjects: 216
Study: 11425511

Group type: EXPERIMENTAL
Intervention: Tryptophan (1g TID for 12 days)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (12 days)
Number of subjects: 98
Study: 9512946

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 200 ml/l of ascites removed, n = 27
Number of subjects: 60

Group type: COMPARATOR
Intervention: Albumin 8 g/l of ascites removed, n = 33
Number of subjects: 60
Study: 7527326

Group type: EXPERIMENTAL
Intervention: Quinapril 10 to 40 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinapril dosages up to 80 mg/day and/or concomitant diuretic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinapril titration from 10 to 40 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinapril with hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinapril ≤ 40 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study: 30691753

Group type: EXPERIMENTAL
Intervention: Combined exercise therapy (closed kinetic chain exercises and proprioception exercises)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24
Study: 28448088

Group type: EXPERIMENTAL
Intervention: Individually tailored dietary counseling for six months; instructed to increase food intake with energy-dense food items, number of meals, and consumption of energy-, protein-, and nutrient-rich snacks.
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no dietary counseling).
Number of subjects: 224
Study: 26761968

Group type: EXPERIMENTAL
Intervention: Thiotriazoline (600 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/d)
Number of subjects: 0
Study: 23403547

Group type: EXPERIMENTAL
Intervention: Proximal nerve resection (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Distal nerve resection (group A)
Number of subjects: 40
Study: 21153445

Group type: EXPERIMENTAL
Intervention: Phe supplementation
Number of subjects: 9
Study: 18595523

Group type: EXPERIMENTAL
Intervention: Aerius 5 mg/d for 12 days
Number of subjects: 75
Study: 16738858

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVT) 4 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham subconjunctival injection
Number of subjects: 27
Study: 12900738

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG), 400 microg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Metoprolol (MET), 50 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML), 5 mg
Number of subjects: 49
Study: 10847214

Group type: EXPERIMENTAL
Intervention: Computerized self‐administered interview
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper‐and‐pencil self‐administered interview
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of parents during the interview
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of siblings during the interview
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of husband, wife, or live‐in partner during the interview
Number of subjects: 0
Study: 9177526

Group type: EXPERIMENTAL
Intervention: Ursocholic acid (900 mg/day)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tauroursocholate (900 mg/day)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (900 mg/day) after 1 month of ursocholic acid or tauroursocholate feeding
Number of subjects: 4
Study: 8415401

Group type: EXPERIMENTAL
Intervention: Buffered solution of didanosine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saline solution of didanosine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Citrate-phosphate buffer sachet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chewable tablet and antacid suspension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buffered solution of didanosine in humans
Number of subjects: 0
Study: 3317334

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30170424

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injections, 0.9% sodium chloride injections as control, administered once per week for 3 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: 0.9% sodium chloride injections (control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injections
Number of subjects: 27
Study: 28850535

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) in TKA
Number of subjects: 55

Group type: COMPARATOR
Intervention: Femoral block
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) in THA
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with 30mg ketorolac
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with ketorolac
Number of subjects: 55
Study: 23738786

Group type: EXPERIMENTAL
Intervention: Text message intervention (LEAP Beep) for 12 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (weight checks only)
Number of subjects: 34
Study: 22457293

Group type: EXPERIMENTAL
Intervention: PCV7 (7-valent pneumococcal conjugate vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 23vP (23-valent unconjugated pneumococcal polysaccharide vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV7 after 23vP
Number of subjects: 0

Group type: COMPARATOR
Intervention: 23vP
Number of subjects: 0
Study: 20370483

Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 840

Group type: COMPARATOR
Intervention: Delayed circumcision (control)
Number of subjects: 840
Study: 19815630

Group type: EXPERIMENTAL
Intervention: Anodal tDCS 10 min 1.5 mA
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Anodal tDCS 20 min 1 mA
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS 10 min 1.5 mA
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 17
Study: 15694942

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg
Number of subjects: 338
Study: 12853045

Group type: EXPERIMENTAL
Intervention: Mechanical heart valve prosthesis
Number of subjects: 556
Study: 10505725

Group type: EXPERIMENTAL
Intervention: 30-mm Microvasive balloon dilator inflated for 15 sec
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 30-mm Microvasive balloon dilator inflated for 60 sec
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 35-mm Microvasive balloon dilator inflated for 15 sec
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 35-mm Microvasive balloon dilator inflated for 60 sec
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 24
Study: 8984862

Group type: EXPERIMENTAL
Intervention: Macintosh blade
Number of subjects: 40

Group type: COMPARATOR
Intervention: McCoy blade
Number of subjects: 40
Study: 2015484

Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia at 28 degrees C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia at 20 degrees C
Number of subjects: 16
Study: 6756273

Group type: EXPERIMENTAL
Intervention: Metoprolol (M)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol (P)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metoprolol (M) and Propranolol (P)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 7
Study: 31901782

Group type: EXPERIMENTAL
Intervention: Pythagorean Self-Awareness Intervention (PSAI)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 30094387

Group type: EXPERIMENTAL
Intervention: Decentralized arm via telemedicine center (virtual study conduct)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional arm via health clinic (onsite study conduct)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Decentralized arm
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional arm
Number of subjects: 23
Study: 27048949

Group type: EXPERIMENTAL
Intervention: Pollen exposure under normal nasal breathing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pollen exposure with nasal blockage
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham exposure with nasal blockage
Number of subjects: 25
Study: 25024314

Group type: EXPERIMENTAL
Intervention: ABT-288 1 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: ABT-288 3 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 21895392

Group type: EXPERIMENTAL
Intervention: Simultaneous presentation
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Spaced presentation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Massed presentation
Number of subjects: 144
Study: 20140523

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy with recombinant human arylsulfatase B (rhASB) at 1 mg/kg weekly for up to 240 weeks
Number of subjects: 56
Study: 18762755

Group type: EXPERIMENTAL
Intervention: Context-sensitive analgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroprotective agents
Number of subjects: 0
Study: 15877184

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX) - Group I (167 U)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX) - Group II (322 U)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX) - Group III (540 U)
Number of subjects: 45
Study: 12600722

Group type: EXPERIMENTAL
Intervention: AAMI patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Older subjects
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal aging
Number of subjects: 43
Study: 10625872

Group type: EXPERIMENTAL
Intervention: PEEP 5 cmH2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PEEP 10 cmH2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PEEP 15 cmH2O
Number of subjects: 10

Group type: COMPARATOR
Intervention: ZEEP (Control)
Number of subjects: 10
Study: 8858268

Group type: EXPERIMENTAL
Intervention: Cilazapril 0.5 mg daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cilazapril 1.0 mg daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg daily
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 1298871

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (OH-TRY) 500 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6370283

Group type: COMPARATOR
Intervention: Propranolol (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (chronic treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol (chronic treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30477333

Group type: EXPERIMENTAL
Intervention: Sun Safe Workplaces (SSW) intervention promoting occupational sun safety policy and education
Number of subjects: 1784
Study: 28322759

Group type: EXPERIMENTAL
Intervention: Steep ramp test (SRT) for predicting Vo2peak
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Steep ramp test (SRT) for predicting Wpeak
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: New prediction model for Vo2peak
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: New prediction model for Wpeak
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: New prediction model for endurance exercise prescription
Number of subjects: 283
Study: 27058799

Group type: EXPERIMENTAL
Intervention: LMWH + rosuvastatin
Number of subjects: 234

Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 234
Study: 25139469

Group type: EXPERIMENTAL
Intervention: Mean-variance regression calibration approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up time regression calibration approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correction methods applied to Women's Health Initiative hormone therapy trials
Number of subjects: 0
Study: 21728788

Group type: EXPERIMENTAL
Intervention: Weighted balloon catheter with 1000 mL fluid bag
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unweighted balloon catheter taped to the thigh
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unweighted balloon catheter
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Weighted balloon catheter
Number of subjects: 60
Study: 19097106

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg contrast agent
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.2 mmol/kg contrast agent
Number of subjects: 24
Study: 17959539

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil combined with sufentanyl
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sufentanyl alone
Number of subjects: 80
Study: 15871189

Group type: EXPERIMENTAL
Intervention: Enalapril for 8 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Losartan for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 42
Study: 10720857

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once daily
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Alfuzosin 2.5 mg thrice daily
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study: 9368810

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle education (Group 1)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard education programme (Group 2)
Number of subjects: 61
Study: 1392679

Group type: EXPERIMENTAL
Intervention: Xylocaine spray with frigen, two applications (20 mg lidocaine)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Xylestesin spray with frigen, two applications (14 mg lidocaine)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Xylestesin spray with frigen, three applications (21 mg lidocaine)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Xylestesin pump spray without frigen, two applications (14 mg lidocaine)
Number of subjects: 130

Group type: COMPARATOR
Intervention: no topical anesthesia
Number of subjects: 130
Study: 3926832

Group type: EXPERIMENTAL
Intervention: Chlorhexidine toothpaste (0.8% chlorhexidine, 0.1% amine fluoride)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Enzyme-containing toothpaste (1.7 U/g glucose oxidase, 8.0 U/g amyloglucosidase, 0.1% amine fluoride)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Positive control (1% Hibitane dental gel)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Negative control (Vademecum MFP Fluor)
Number of subjects: 9